Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study
Jitao Wang,Qiran Zhang,Jingwen Ai,Dengxiang Liu,Chuan Liu,Huiling Xiang,Ye Gu,Ying Guo,Jiaojian Lv,Yifei Huang,Yanna Liu,Dan Xu,Shubo Chen,Jinlong Li,Qianqian Li,Jing Liang,Li Bian,Zhen Zhang,Xiaoqing Guo,Yinong Feng,Luxiang Liu,Xuying Zhang,Yanliang Zhang,Faren Xie,Shujun Jiang,Wei Qin,Xiaodong Wang,Wei Rao,Qun Zhang,Qiuju Tian,Ying Zhu,Qingwei Cong,Juan Xu,Zhiyun Hou,Nina Zhang,Aiguo Zhang,Hongmei Zu,Yun Wang,Zhaolan Yan,Xiufang Du,Aifang Hou,Yan Yan,Yuanwang Qiu,Hangyuan Wu,Shengjuan Hu,Yanhong Deng,Jiansong Ji,Jie Yang,Jiansheng Huang,Zhongwei Zhao,Shengqiang Zou,Hailei Ji,Guohong Ge,Li Zhong,Song He,Xiaosong Yan,Bian Ba Yangzhen,Ci Qu,Liting Zhang,Shiying Yang,Xiaoqin Gao,Muhan Lv,Qingliang Zhu,Xinxin Xu,Qing-Lei Zeng,Xiaolong Qi,Wenhong Zhang
DOI: https://doi.org/10.1007/s12072-022-10332-9
IF: 9.029
2022-04-09
Hepatology International
Abstract:BackgroundData on safety and immunogenicity of coronavirus disease 2019 (COVID-19) vaccination in patients with compensated (C-cirrhosis) and decompensated cirrhosis (D-cirrhosis) are limited.MethodsIn this prospective multicenter study, adult participants with C-cirrhosis and D-cirrhosis were enrolled and received two doses of inactivated whole-virion COVID-19 vaccines. Adverse events were recorded within 14 days after any dose of vaccination, and serum samples of enrolled patients were collected and tested for SARS-CoV-2 neutralizing antibodies at least 14 days after the second dose. Risk factors for negative neutralizing antibody were analyzed.ResultsIn total, 553 patients were enrolled from 15 centers in China, including 388 and 165 patients with C-cirrhosis and D-cirrhosis. The vaccines were well tolerated, most adverse reactions were mild and transient, and injection site pain (23/388 [5.9%] vs 9/165 [5.5%]) and fatigue (5/388 [1.3%] vs 3/165 [1.8%]) were the most frequently local and systemic adverse events in both the C-cirrhosis and D-cirrhosis groups. Overall, 4.4% (16/363) and 0.3% (1/363) of patients were reported Grades 2 and 3 alanine aminotransferase (ALT) elevations (defined as ALT > 2 upper limit of normal [ULN] but ≤ 5 ULN, and ALT > 5 ULN, respectively). The positive rates of COVID-19 neutralizing antibodies were 71.6% (278/388) and 66.1% (109/165) in C-cirrhosis and D-cirrhosis groups. Notably, Child–Pugh score of B and C levels was an independent risk factor of negative neutralizing antibody.ConclusionsInactivated COVID-19 vaccinations are safe with acceptable immunogenicity in cirrhotic patients, and Child–Pugh score of B and C levels is associated with hyporesponsive to COVID-19 vaccination.
gastroenterology & hepatology